BCAX logo

BCAX
Bicara Therapeutics

83
Mkt Cap
$1.36B
Volume
607,386.00
52W High
$21.63
52W Low
$7.80
PE Ratio
-8.27
BCAX Fundamentals
Price
$21.10
Prev Close
$20.85
Open
$21.02
50D MA
$17.49
Beta
1.73
Avg. Volume
610,609.08
EPS (Annual)
-$2.52
P/B
2.94
Rev/Employee
$0.00
$507.12
Loading...
Loading...
News
all
press releases
Bicara Therapeutics (NASDAQ:BCAX) Sets New 12-Month High - Here's Why
Bicara Therapeutics (NASDAQ:BCAX) Sets New 52-Week High - Time to Buy...
MarketBeat·10h ago
News Placeholder
More News
News Placeholder
HC Wainwright Has Bullish Estimate for BCAX Q1 Earnings
Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Analysts at HC Wainwright boosted their Q1 2026 earnings per share estimates for Bicara Therapeutics in a research report issued on Tuesday...
MarketBeat·5d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year High Following Analyst Upgrade
Bicara Therapeutics (NASDAQ:BCAX) Sets New 12-Month High on Analyst Upgrade...
MarketBeat·6d ago
News Placeholder
Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 54.9% in Bicara Therapeutics Inc. (BCAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·6d ago
News Placeholder
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?
Here is how CareCloud, Inc. (CCLD) and Bicara Therapeutics Inc. (BCAX) have performed compared to their sector so far this year.
Zacks·6d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at The Goldman Sachs Group
The Goldman Sachs Group increased their target price on Bicara Therapeutics from $14.00 to $16.00 and gave the company a "neutral" rating in a research note on Tuesday...
MarketBeat·7d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) Given "Outperform" Rating at Wedbush
Wedbush reiterated an "outperform" rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday...
MarketBeat·7d ago
News Placeholder
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at Wells Fargo & Company
Wells Fargo & Company upped their price target on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the stock an "equal weight" rating in a research report on Tuesday...
MarketBeat·7d ago
News Placeholder
Citizens Jmp Reiterates "Market Outperform" Rating for Bicara Therapeutics (NASDAQ:BCAX)
Citizens Jmp restated a "market outperform" rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday...
MarketBeat·7d ago
News Placeholder
Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday
Top analysts changed outlook on top names. See all changes on analyst ratings page. BTIG & HCW cut price targets, Needham & BMO raised, Baird bcut.read more...
Benzinga·7d ago
<
1
2
...
>

Latest BCAX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.